Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode hundreds of pages of oncology jargon in Processa Pharmaceuticals’ filings? Each Form 10-K outlines how the company funds its Next Generation Chemotherapy (NGC) pipeline, while every 8-K details new clinical milestones or FDA feedback that can move PCSA’s share price overnight. Missing one paragraph could mean overlooking a cash-raising shelf registration or a trial setback.
StockTitan’s AI reads the documents for you. Our platform delivers plain-English summaries of the Processa Pharmaceuticals annual report 10-K simplified, highlights R&D spending trends in the latest Processa Pharmaceuticals quarterly earnings report 10-Q filing, and flags dilution risks buried in S-3 prospectuses. Need real-time alerts? We stream Processa Pharmaceuticals Form 4 insider transactions as soon as they hit EDGAR, so you can track executive confidence without wading through pdfs.
Use our guided view to jump straight to the sections investors ask about most:
- Cash runway projections and trial budgets in 10-Q MD&A
- NGC clinical results and FDA responses in 8-K material events explained
- Processa Pharmaceuticals insider trading Form 4 transactions with AI-generated context on each buy or sell
- Board pay packages inside the Processa Pharmaceuticals proxy statement executive compensation
Whether you’re asking “How do I read Processa’s 10-K?” or searching for “understanding Processa Pharmaceuticals SEC documents with AI,” StockTitan delivers every filing type—10-K, 10-Q, 8-K, S-3, SC 13G, and more—complete with expert notes and real-time updates. Spend minutes, not hours, turning dense biotech disclosures into actionable insight.
A Schedule 13G filing reveals that CVI Investments and Heights Capital Management have acquired a significant 9.9% stake in Processa Pharmaceuticals, holding 2,663,078 shares. The position consists of 2,200,000 common shares and additional warrants.
Key details of the investment:
- CVI Investments (Cayman Islands) and Heights Capital Management (Delaware) share voting and dispositive power over all shares
- Heights Capital Management serves as investment manager to CVI Investments
- Ownership includes pre-funded warrants and other warrants with a 9.99% exercise limitation
- Total outstanding shares reported as 26,194,356 as of June 18, 2025
The filing confirms the securities were not acquired to influence control of Processa Pharmaceuticals. The transaction appears to be a passive investment, with both entities filing jointly through their authorized representative Sarah Travis on June 24, 2025.
3i, LP, 3i Management LLC and Maier Joshua Tarlow have filed a Schedule 13G reporting aggregate beneficial ownership of 1,681,944 Processa Pharmaceuticals (PCSA) common shares, equal to 4.9 % of the outstanding stock. The shares are issuable on exercise of warrants obtained in the June 2025 public offering and are subject to a 4.99 % ownership blocker.
The filing constitutes an exit filing; all other securities acquired in the offering have been disposed, reducing the group’s holdings below the 5 % reporting threshold. Voting and dispositive power over the warrants is shared among the three reporting persons.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) filed an 8-K disclosing a capital raise that closed on 18 Jun 2025. The company entered into Securities Purchase Agreements with accredited investors for a best-efforts registered public offering consisting of (i) 14.31 million common shares, (ii) 13.69 million pre-funded warrants and (iii) 28 million five-year common warrants, all priced at a combined $0.25 per share (or $0.2499 when issued as a pre-funded warrant).
Key commercial terms
- Common Warrants: exercise price $0.25, immediately exercisable, expire five years from issuance.
- Pre-Funded Warrants: exercise price $0.0001, immediately exercisable until fully exercised.
- Placement Agent: H.C. Wainwright & Co. receives 7.0% cash fee on gross proceeds, up to $165,950 in expenses, and 1.12 million placement-agent warrants at $0.3125.
- Gross proceeds: approximately $6.3 million, before fees and expenses; additional proceeds possible upon warrant exercise.
Use of proceeds: fund the Phase 2 clinical trial of NGC-Cap and for general working capital.
Lock-up & issuance restrictions:
- No issuance of equity or equivalents for 60 days.
- No ATM, equity-line or variable-rate transactions for six months, except certain transactions with the Placement Agent after 90 days.
The securities were issued under the company’s effective S-1 (Reg. No. 333-287997). Exhibits include the forms of warrants, the purchase agreement and the related press release.
Investor takeaways: The raise strengthens near-term liquidity and advances a core clinical asset, but could increase the fully-diluted share count by up to ~57 million shares, representing meaningful dilution at a discounted price point.
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
What is the market cap of Processa Pharmaceuticals (PCSA)?
